CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −367 | $235.25 | $86K | 18,471 |
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −3,506 | $235.40 | $825K | 14,965 |
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −514 | $235.25 | $121K | 14,451 |
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Sale 10b5-1 | −4,726 | $235.43 | $1.1M | 9,725 |
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −367 | 105 | ||
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −3,506 | 3,589 | ||
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −514 | 169 | ||
| 2025-03-03 | Ghoshal Kaushik Chief Commercial Officer, SaaS | Option exercise · ResMed Common Stock Options 10b5-1 | −4,726 | 5,882 | ||
| 2025-03-03 | Rider Michael J Global General Counsel | Sale 10b5-1 | −64 | $234.10 | $15K | 8,910 |
| 2025-02-10 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $238.98 | $239K | 91,864 |
| 2025-02-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,481 |
| 2025-02-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $236.77 | $1.9M | 455,472 |
| 2025-02-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 72,083 | ||
| 2025-02-05 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $242.11 | $484K | 77,218 |
| 2025-02-03 | Rider Michael J Global General Counsel | Sale 10b5-1 | −64 | $242.42 | $16K | 8,974 |
| 2025-01-08 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $234.04 | $234K | 92,864 |
| 2025-01-02 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $230.99 | $462K | 79,218 |
| 2025-01-02 | Rider Michael J Global General Counsel | Sale 10b5-1 | −75 | $230.99 | $17K | 9,038 |
| 2024-12-09 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $244.23 | $244K | 93,864 |
| 2024-12-04 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $245.65 | $491K | 81,218 |
Page 10 of 18 · 360 trades